Importantly, despite intensive glucocorticoid and immunosuppressant therapy, patients with anti-MDA5+ DM-related ILD/RP-ILD generally demonstrate poor treatment responses and dismal prognoses (3), posing a substantial challenge to clinicians. Here, IFIH1 is linked to interstitial lung disease.